S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
S&P 500   3,315.57 (+1.05%)
DOW   27,288.18 (+0.52%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:ENTX

Entera Bio Stock Forecast, Price & News

$1.32
-0.01 (-0.75 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.31
Now: $1.32
$1.37
50-Day Range
$1.05
MA: $1.35
$1.75
52-Week Range
$1.00
Now: $1.32
$3.40
Volume46,383 shs
Average Volume292,305 shs
Market Capitalization$15.09 million
P/E RatioN/A
Dividend YieldN/A
Beta1.37
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.20 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ENTX
CUSIPN/A
CIKN/A
Phone972-2532-7151

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$240,000.00
Book Value$1.04 per share

Profitability

Net Income$-10,800,000.00

Miscellaneous

Employees19
Market Cap$15.09 million
Next Earnings Date11/19/2020 (Estimated)
OptionableNot Optionable
$1.32
-0.01 (-0.75 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ENTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Entera Bio (NASDAQ:ENTX) Frequently Asked Questions

How has Entera Bio's stock price been impacted by Coronavirus?

Entera Bio's stock was trading at $2.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ENTX shares have decreased by 52.5% and is now trading at $1.32.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Entera Bio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Entera Bio
.

When is Entera Bio's next earnings date?

Entera Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 19th 2020.
View our earnings forecast for Entera Bio
.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd (NASDAQ:ENTX) released its earnings results on Thursday, August, 20th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.05.
View Entera Bio's earnings history
.

What price target have analysts set for ENTX?

1 brokerages have issued 1-year target prices for Entera Bio's shares. Their forecasts range from $8.00 to $8.00. On average, they expect Entera Bio's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 506.1% from the stock's current price.
View analysts' price targets for Entera Bio
.

Are investors shorting Entera Bio?

Entera Bio saw a decline in short interest in August. As of August 31st, there was short interest totaling 44,400 shares, a decline of 28.2% from the August 15th total of 61,800 shares. Based on an average daily trading volume, of 709,700 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the shares of the stock are short sold.
View Entera Bio's Short Interest
.

Who are some of Entera Bio's key competitors?

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Canopy Growth (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

Who are Entera Bio's key executives?

Entera Bio's management team includes the following people:
  • Dr. Phillip Schwartz Ph.D., CEO & Director (Age 57)
  • Dr. Hillel Galitzer, Chief Operating Officer (Age 41)
  • Dr. Roger J. Garceau, Chief Devel. Advisor & Director (Age 65)
  • Dr. Arthur C. Santora II, Chief Medical Officer

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Phoenix Holdings Ltd. (0.00%) and Wedbush Securities Inc. (0.00%).

Which major investors are selling Entera Bio stock?

ENTX stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd..

Which major investors are buying Entera Bio stock?

ENTX stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of Entera Bio?

Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $1.32.

How big of a company is Entera Bio?

Entera Bio has a market capitalization of $15.09 million and generates $240,000.00 in revenue each year. Entera Bio employs 19 workers across the globe.

What is Entera Bio's official website?

The official website for Entera Bio is www.enterabio.com.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at 972-2532-7151 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.